Full Text
How Does the Additional Benefit Extend of Orphan Drugs Impact Price Negotiations in the German Outpatient Sector?

Abstract

Authors

R Schwarz M Freiberg

Back to Volume 19, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×